Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)
Basal Cell Nevus Syndrome Gorlin syndrome Basal cell nevus syndrome BCNS Nevoid basal cell carcinoma syndrome Basal cell carcinoma Hedgehog Surgically eligible basal cell carcinomas Patidegib Carcinoma Carcinoma, Basal Cell Nevus Nevus, Pigmented Syndrome Veratrum Alkaloids Patidegib Topical Gel, 2% Patidegib Topical Gel, Vehicle Patidegib Topical Gel, 2%,
Lead Scientist at UCSF
- Sarah Arron
My research focuses on the pathogenesis of cutaneous squamous cell carcinoma. As a Mohs Micrographic surgeon in the department of Dermatology, I lead the High Risk Skin Cancer Program, a practice devoted to the care of patients at risk for skin cancer due to solid organ transplant and other iatrogenic immunosuppression, HIV infection, and genetic conditions predisposing to cutaneous malignancy.
- in progress, not accepting new patients
- Start Date
- Completion Date
- PellePharm, Inc.
- Phase 3
- Study Type
- Last Updated